流式细胞术微小残留病定量可为T细胞急性淋巴细胞白血病提供可靠的风险分层
该研究纳入274例接受NOPHO-ALL2008方案治疗的T细胞急性淋巴细胞白血病(T-ALL)患者,比较六色流式细胞术(FCM)与实时定量PCR检测微小残留病(MRD)的风险分层价值。第29天FCM-MRD≥10⁻³者复发风险比为3.55(95%CI 1.4-9.0,p=0.008),PCR-MRD≥10⁻³者为5.6(95%CI 2.0-16,p=0.001)。FCM-MRD可在无PCR标记时用于风险分层。
要点
- 初诊时93%患者有FCM标记、84%有PCR标记,两者结合99.3%(272/274)可监测MRD。
- 第29天FCM-MRD≥10⁻³者复发HR为3.55(95%CI 1.4-9.0,p=0.008)。
- 第29天PCR-MRD≥10⁻³者复发HR为5.6(95%CI 2.0-16,p=0.001)。
核心结论
- FCM-MRD可为T-ALL提供可靠的风险预测,在无PCR标记时可用于风险分层。
- FCM-MRD可早期识别适合减低强度治疗的患者,但这需要进一步研究。
研究设计与样本
- 研究纳入274例接受NOPHO-ALL2008方案治疗的T-ALL患者。
- MRD采用六色流式细胞术(FCM)和实时定量PCR检测。
- 第29天PCR-MRD( cutoff 10⁻³)用于风险分层。
主要发现
- 初诊时93%患者有FCM标记用于MRD监测,84%有PCR标记,两者结合99.3%(272/274)有标记。
- 校正年龄和白细胞计数后,第29天FCM-MRD≥10⁻³者复发风险比为3.55(95%CI 1.4-9.0,p=0.008),PCR-MRD≥10⁻³者为5.6(95%CI 2.0-16,p=0.001),均与MRD<10⁻³比较。
- 第29天按MRD 10⁻⁴-<10⁻³分入中危治疗的患者,其5年无事件生存与MRD<10⁻⁴或不可测的中危患者相似,与监测方法无关。
- 第15天FCM-MRD<10⁻⁴者的累积复发发生率为2.3%(95%CI 0-6.8,n=59)。
局限性
- FCM-MRD可早期识别适合减低强度治疗的患者,但这需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Minimal residual disease (MRD) measured by PCR of clonal IgH/TCR rearrangements predicts relapse in T-cell acute lymphoblastic leukemia (T-ALL) and serves as risk stratification tool. Since 10% of patients have no suitable PCR-marker, we evaluated flowcytometry (FCM)-based MRD for risk stratification. We included 274 T-ALL patients treated in the NOPHO-ALL2008 protocol. MRD was measured by six-color FCM and real-time quantitative PCR. Day 29 PCR-MRD (cut-off 10-3) was used for risk stratification. At diagnosis, 93% had an FCM-marker for MRD monitoring, 84% a PCR-marker, and 99.3% (272/274) had a marker when combining the two. Adjusted for age and WBC, the hazard ratio for relapse was 3.55 (95% CI 1.4-9.0, p = 0.008) for day 29 FCM-MRD ≥ 10-3 and 5.6 (95% CI 2.0-16, p = 0.001) for PCR-MRD ≥ 10-3 compared with MRD < 10-3. Patients stratified to intermediate-risk therapy on day 29 with MRD 10-4-<10-3 had a 5-year event-free survival similar to intermediate-risk patients with MRD < 10-4 or undetectable, regardless of method for monitoring. Patients with day 15 FCM-MRD < 10-4 had a cumulative incidence of relapse of 2.3% (95% CI 0-6.8, n = 59). Thus, FCM-MRD allows early identification of patients eligible for reduced intensity therapy, but this needs further studies. In conclusion, FCM-MRD provides reliable risk prediction for T-ALL and can be used for stratification when no PCR-marker is available.
引用
- Modvig S, Madsen HO, Siitonen SM, et al. Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. Leukemia. 2018. PMID: 30552401. doi:10.1038/s41375-018-0307-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。